Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cantor Fitzgerald
Healthtrust
Mallinckrodt
Federal Trade Commission
Accenture
Cerilliant
Moodys
Queensland Health

Generated: April 26, 2018

DrugPatentWatch Database Preview

OPTIMARK Drug Profile

« Back to Dashboard

When do Optimark patents expire, and what generic alternatives are available?

Optimark is a drug marketed by Liebel-flarsheim and is included in three NDAs.

The generic ingredient in OPTIMARK is gadoversetamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadoversetamide profile page.
Drug patent expirations by year for OPTIMARK
Pharmacology for OPTIMARK
Synonyms for OPTIMARK
(Gadoversetamide) (8,11-bis(carboxymethyl)-14-(2-((2-methoxyethyl)amino)-2-oxoethyl)-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)), gadolinium
(N,N-Bis(2-((carboxymethyl)(((2-methoxyethyl)carbamoyl)methyl)amino)ethyl)glycinato(3-))gadolinium
[8,11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amno]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)] gadolinium
131069-91-5
2-[bis[2-[[2-(2-methoxyethylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+)
AC1L9FJP
AC1O5KIJ
AKOS015896615
CHEBI:31644
D01646
D0X0GI
DB00538
DTXSID10156865
gadolinium 8,11-bis(carboxylatomethyl)-14-{2-[(2-methoxyethyl)amino]-2-oxoethyl}-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oate
gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
gadolinium(3+) ion 2-[bis({2-[(carboxylatomethyl)({[(2-methoxyethyl)carbamoyl]methyl})amino]ethyl})amino]acetate
Gadoversetamid
Gadoversetamida
GADOVERSETAMIDE
Gadoversetamide (JAN/USP/INN)
Gadoversetamide [USAN:INN:BAN]
Gadoversetamidum
HSDB 7550
I06-2302
LP071524
LS-186531
MRI contrast agent, Mallinckrodt
Optimark (TN)
Optimark In Plastic Container
RLM74T3Z9D
SCHEMBL237265
UNII-RLM74T3Z9D

US Patents and Regulatory Information for OPTIMARK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-003 Dec 8, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-004 Dec 8, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for OPTIMARK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999 ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 ➤ Sign Up ➤ Sign Up
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fuji
Fish and Richardson
Johnson and Johnson
Julphar
McKesson
Boehringer Ingelheim
Queensland Health
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.